Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) had its price objective upped by Chardan Capital from $19.50 to $21.00 in a research report report published on Tuesday, August 8th, MarketBeat reports. They currently have a buy rating on the stock.
TRHC has been the subject of several other reports. Zacks Investment Research raised Tabula Rasa Healthcare from a sell rating to a hold rating in a research report on Tuesday, May 16th. Stifel Nicolaus reaffirmed a buy rating and issued a $16.00 target price on shares of Tabula Rasa Healthcare in a research report on Friday, July 14th. Finally, UBS AG reaffirmed a buy rating and issued a $17.00 target price (down from $18.00) on shares of Tabula Rasa Healthcare in a research report on Thursday, May 25th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Tabula Rasa Healthcare presently has an average rating of Buy and an average target price of $17.83.
Tabula Rasa Healthcare (NASDAQ TRHC) traded up 2.66% during mid-day trading on Tuesday, hitting $17.77. 49,822 shares of the stock were exchanged. The company’s market cap is $307.17 million. Tabula Rasa Healthcare has a one year low of $10.39 and a one year high of $18.25. The company has a 50-day moving average price of $15.45 and a 200-day moving average price of $14.23.
Tabula Rasa Healthcare (NASDAQ:TRHC) last posted its quarterly earnings data on Monday, August 7th. The company reported $0.06 earnings per share for the quarter, meeting the consensus estimate of $0.06. Tabula Rasa Healthcare had a negative return on equity of 9.58% and a negative net margin of 10.27%. The company had revenue of $29.70 million during the quarter, compared to analysts’ expectations of $27.84 million. Tabula Rasa Healthcare’s quarterly revenue was up 32.6% compared to the same quarter last year. Analysts forecast that Tabula Rasa Healthcare will post $0.40 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Tabula Rasa Healthcare Inc. (TRHC) Given New $21.00 Price Target at Chardan Capital” was originally reported by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/chardan-capital-raises-tabula-rasa-healthcare-inc-trhc-price-target-to-21-00-updated.html.
In other Tabula Rasa Healthcare news, Director Gordon Tunstall sold 22,759 shares of Tabula Rasa Healthcare stock in a transaction on Monday, June 12th. The stock was sold at an average price of $13.76, for a total transaction of $313,163.84. Following the completion of the transaction, the director now directly owns 5,565 shares of the company’s stock, valued at $76,574.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Calvin H. Knowlton sold 8,000 shares of the firm’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $17.21, for a total value of $137,680.00. Following the completion of the sale, the chief executive officer now owns 918,362 shares of the company’s stock, valued at $15,805,010.02. The disclosure for this sale can be found here. Over the last three months, insiders have sold 46,759 shares of company stock valued at $676,604. Company insiders own 45.80% of the company’s stock.
Several hedge funds have recently made changes to their positions in TRHC. California State Teachers Retirement System raised its stake in shares of Tabula Rasa Healthcare by 60.2% in the second quarter. California State Teachers Retirement System now owns 16,500 shares of the company’s stock worth $248,000 after buying an additional 6,200 shares during the period. State Street Corp raised its stake in shares of Tabula Rasa Healthcare by 38.9% in the second quarter. State Street Corp now owns 69,673 shares of the company’s stock worth $1,051,000 after buying an additional 19,506 shares during the period. Intrinsic Edge Capital Management LLC acquired a new stake in shares of Tabula Rasa Healthcare during the second quarter worth $461,000. Hood River Capital Management LLC raised its stake in shares of Tabula Rasa Healthcare by 7.5% in the second quarter. Hood River Capital Management LLC now owns 825,225 shares of the company’s stock worth $12,420,000 after buying an additional 57,724 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Tabula Rasa Healthcare by 13.4% in the second quarter. Vanguard Group Inc. now owns 236,964 shares of the company’s stock worth $3,566,000 after buying an additional 27,997 shares during the period. Institutional investors own 25.28% of the company’s stock.
Tabula Rasa Healthcare Company Profile
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.